ArticleInvestigational new drugs2022

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.

Corinne Maurice-Dror et al.PubMed ↗Publisher ↗

No numbers read from the abstract.